Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Brass

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Molecules (Basel, Switzerland)|March 6, 2021
Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin TreatmentLena Berning, David Schlütermann, Annabelle Friedrich, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Frontiers in Microbiology|May 18, 2023
Production of tailored hydroxylated prodiginine showing combinatorial activity with rhamnolipids against plant-parasitic nematodesD F Kossmann, M Huang, R Weihmann, et al.
Alimentary Pharmacology & Therapeutics|August 5, 2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)S Zeuzem, R Flisiak, J M Vierling, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Molecules (Basel, Switzerland)|March 6, 2021
Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin TreatmentLena Berning, David Schlütermann, Annabelle Friedrich, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Frontiers in Microbiology|May 18, 2023
Production of tailored hydroxylated prodiginine showing combinatorial activity with rhamnolipids against plant-parasitic nematodesD F Kossmann, M Huang, R Weihmann, et al.
Alimentary Pharmacology & Therapeutics|August 5, 2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)S Zeuzem, R Flisiak, J M Vierling, et al.
Pageof 4